Logo image
Deciphering the Genomic Landscape of Oropharyngeal Squamous Cell Carcinoma: Distinct Mutation Patterns in Disease
Journal article   Open access   Peer reviewed

Deciphering the Genomic Landscape of Oropharyngeal Squamous Cell Carcinoma: Distinct Mutation Patterns in Disease

Beau Hsia, Gabriel Bitar, Pedro S Bonilla, Vinay D Veluvolu, Nathan Tran, Saif Alshaka, Eli Oved, Bhavish Aubeelauck, Hassan Nur, Abubakar Tauseef, …
Life (Basel, Switzerland), Vol.16(2), p.282
02/06/2026
PMID: 41752918

Abstract

somatic mutations AACR Project GENIE genomic profiling targeted therapy PIK3CA oropharyngeal squamous cell carcinoma TP53
We aimed to characterize the somatic mutational landscape of oropharyngeal squamous cell carcinoma (OPSCC) and identify potential genomic drivers of tumor progression and therapeutic resistance using the AACR GENIE database. Retrospective genomic analysis was employed. We used publicly available data from the American Association for Cancer Research (AACR) Project GENIE database accessed via cBioPortal. We analyzed 412 tumor samples from 401 patients diagnosed with OPSCC. Somatic mutations, clinical variables and tumor characteristics were extracted and analyzed. Statistical comparisons of mutation frequencies across gender and tumor stage (primary vs. metastatic) were conducted. Co-occurrence and mutual exclusivity analyses were performed to identify significant genomic patterns. The most frequently mutated genes included (30.1%), (26.0%), and (21.6%). Gender-specific analyses suggested potential enrichment of and mutations in females and of in males. Distinct mutation patterns were observed between primary and metastatic tumors; primary tumors were enriched for mutations in and , while metastatic lesions harbored unique alterations in genes like and , suggesting pathways involved in immune evasion and chromosomal instability may drive disease progression. Co-occurrence was noted between and , and mutual exclusivity between and . This study identifies distinct genomic signatures in OPSCC subgroups, highlighting candidate biomarkers in pathways like PI3K/AKT signaling that warrant further investigation. Validating these markers in prospective trials is a critical next step to translate these findings into personalized therapeutic strategies for OPSCC patients.
url
https://doi.org/10.3390/life16020282View
Published (Version of record) Open

Metrics

1 Record Views

Details

Logo image